<DOC>
	<DOCNO>NCT00387517</DOCNO>
	<brief_summary>The purpose trial evaluate safety efficacy combination therapy aliskiren/hydrochlorothiazide ( HCTZ ) 150/25 mg 300/25 mg compare HCTZ 25 mg patient hypertension show response HCTZ 25 mg 4-week period .</brief_summary>
	<brief_title>Safety/Efficacy Combo Therapy With Aliskiren &amp; Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female outpatient 18 year old old . Patients diagnosis hypertension define follow : Newly diagnose patient patient treated hypertension within 4 week prior Visit 1 must msDBP &gt; = mmHg &lt; 110 mmHg Visit 1 . All patient treat hypertension within 4 week prior Visit 1 must msDBP &gt; = 85 mmHg &lt; 110 mmHg Visit 2 . All patient must msDBP &gt; = 90 mmHg &lt; 110 mmHg Visit 5 . Patients eligible consent participate study Severe hypertension ( msDBP &gt; = 110 mmHg and/or MSSBP &gt; =180 mmHg ) . Previous current diagnosis heart failure . History hypertensive encephalopathy cerebrovascular accident , transient ischemic cerebral attack , myocardial infarction , coronary bypass surgery , percutaneous coronary intervention . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diastolic</keyword>
	<keyword>systolic</keyword>
	<keyword>hypertension</keyword>
	<keyword>aliskiren</keyword>
	<keyword>blood pressure</keyword>
	<keyword>hydrochlorothiazide</keyword>
	<keyword>HCTZ</keyword>
</DOC>